Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 05338F306
Event date: 2025-12-31
- Filing-level shares
- 1,187,300.00
- Percent of class
- 6.4%
- OrbiMed Advisors LLC
Shares: 1,187,300.00 · Class: 6.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-26-000187
- Form type
- SCHEDULE 13G/A
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership